Sobin is the CEO of Aquavit. She brings wealth of experience in Management, Marketing, and Research in pharmaceuticals, devices, and biologics from recognized brand BOTOX® to a $7.5B oncology portfolio. Prior to Aquavit, she served as Chair, Portfolio Committee for BOTOX, leading a multidisciplinary team of executives assessing new indications and valuations for new technologies at Allergan. Her out-of the box thinking, drive and execution was recognized by every organization she served. Her breadth of experience in various therapeutic areas includes neuroscience, dermatology, infectious disease, allergy & immunology and oncology, which lead to over 25 inventions. She is a trained pharmacoeconomist and has over 60 publications. She served at the US Department of Health and Human Services, the Division of Drug Marketing, Advertising and Communications of the Food and Drug Administration (FDA DDMAC) providing guidance on the FDA Modernization Act. She received her B.A. Honors in Mathematics with Magna Cum Laude from University of Missouri-Columbia and M.P.H and post-doctoral fellowship in Biostatistics, Regulatory Affairs and Pharmacoeconomics from Yale School of Medicine. She was the opening keynote speaker for the Big data in Pharma conference in Philadelphia and is currently serving as Director of the Board at AYAPH (Association of Yale Alumni in Public Health) and Chair, Business and Industry Committee, Member of Education Council of the Board at American Skin Association and Advisory Board Member of University of Missouri Precision Medicine Center .